Business Context and Reporting Period
This Form 8-K was filed by Coherus BioSciences, Inc. on July 17, 2018. The report addresses Item 8.01 (Other Events) concerning the regulatory status of the Company's pegfilgrastim biosimilar candidate, CHS-1701, with the European Medicines Agency (EMA).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements.
Material Changes
The primary material change reported is the resolution of regulatory issues regarding the CHS-1701 application:
- Following the June 27, 2018 CHMP meeting, outstanding issues were identified regarding Day 180 Responses.
- The Company submitted a full response to these issues on July 3, 2018.
- The Company received a joint assessment report from the (co)-Rapporteurs concluding that the outstanding issues were satisfactorily addressed and no further concerns remain.
Guidance, Outlook, and Risks
Outlook: The Company expects the CHS-1701 application to be included on the agenda for the July 2018 CHMP meeting, as the joint assessment report is currently under review by the CHMP.
Risks and Contingencies: While the rapporteurs have cleared the outstanding issues, final approval remains contingent upon the CHMP's review and subsequent decision at the July 2018 meeting.
Investor Verification Checklist
- Confirm the outcome of the July 2018 CHMP meeting regarding the CHS-1701 application.
- Verify the timeline for potential European Commission marketing authorization following a positive CHMP opinion.
- Monitor for any additional regulatory requirements or delays not disclosed in this report.